Biogen Idec (BIIB) Sinks 8% After ALS Drug Fails, Development Stopped
Tweet Send to a Friend
Biogen Idec (NASDAQ: BIIB) is trading down 8 percent after reporting top-line results of EMPOWER, a Phase 3 trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
